archive-au.com » AU » T » TRADERDEALER.COM.AU

Total: 417

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • Stock Market Analysis: The Bulls Are Getting The Upper Hand | Online Stockmarket Trading Update
    8 after reporting a 33 drop in 1Q profit and Banco Santander dropped 3 4 after reporting a 24 drop in 1Q profit as itsprovisions for bad loans jumped In London the FTSE 100 index last closed up 0 5 or 29 points at 5 749 the German DAX was last up 0 5 or 35 points at 6 740 while in France the CAC was last down 0 1 or 4 points at 3 229 Spain was down 1 3 and Italy ended down 0 7 Asian Markets Asian stock markets finished mostly higher yesterday on news that the Bernanke Put was still in play In Japan investors were cautious ahead of the Bank of Japan s policy meeting today The market has already factored in an Y10 trillion expansion of the BoJ s asset purchase program Chinese shares ended flat as the market holds below the 2450 level while in Hong Kong the market continues to hover around the 21 000 level In China the SSE Composite last closed down 0 1 or 2 points at at 2 404 while in Hong Kong the Hang Seng Index last closed up 0 8 or 163 points at 20 809 and in Japan the Nikkei 225 Index was closed flat or 1 points at 9 562 South Korean KOSPI was down 0 1 for the session while the Indian market closed down 0 1 Commodities The Dollar Index was lower at 79 18 on a higher Euro while the Australian Dollar last traded lower at 1 0356 Commodities prices traded generally lower For the session the Benchmark crude NYMEX for April delivery was down 0 5 or US0 51 settled at US104 04 Copper prices are backing off key resistance level as Copper for April delivery was down 0 1 or 0 3 cents at US3 7645 April gold was down 0 3 or US5 10 at US1 654 50 ASX News Today OSH Oil Search says it is reviewing bids from potential joint venture partners in its Papua New Guinea gas projects LEI Leighton Holdings says its Middle East operation is part of a joint venture awarded a US169 million contract for work on a mine in Saudi Arabia LLC Lend Lease Group property developer says fraudulent activities that prompted a legal investigation into an arm of Lend Lease in the United States no longer occur MTN Marathon Resources the uranium explorer will use a 5 million compensation payment from the South Australian government to investigate new projects NWS Rupert Murdoch has declared he had never asked a prime minster for anything as the UK inquiry into media ethics claimed its first political scalp OZL OZ Minerals lifted its production of gold and copper in the first three months of the year but costs rose due to heavy rains QRN Rail operator QR National and Atlas Iron are looking at building a new railway linking mines in WA s Pilbara region to Port Hedland SGT SingTel says millions of

    Original URL path: http://blog.traderdealer.com.au/2012/04/27/stock-market-analysis-the-bulls-are-getting-the-upper-hand/ (2013-02-03)
    Open archived version from archive


  • Novogen Subsidiary Granted US Patent | Online Stockmarket Trading Update
    portfolio now includes 15 issued US patents at least 12 additional US patent applications and more than 70 issued foreign patents and 50 foreign patent applications Marshall Edwards Inc is a San Diego based oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism Novogen Limited NRT is an Australian biotechnology company based in Sydney Australia Novogen conducts research and development on oncology therapeutics through its subsidiary Marshall Edwards Inc and is developing glucan technology through its subsidiary Glycotex Inc www novogen com Tags Cancer treatment Marshall Edwards Novogen NRT Patent Granted ASX Company News Phylogica Granted Australian Patent Stock Market Analysis The Bulls Are Getting The Upper Hand This entry was posted on Friday April 27th 2012 at 6 08 am and is filed under ASX Company News You can follow any responses to this entry through the RSS 2 0 feed You can leave a response or trackback from your own site Leave a Reply Click here to cancel reply Name required Mail will not be published required Website RSS Feed Twitter Follow Us Sign up to our free weekly e newsletter Feel inspired Start trading Recent Post Markets Cap Best January Performance for Over a Decade Weekly Market Wrap The Covered Call Collar Part 3 1 of Options Trading for All Types of Market Environments Stock Market Analysis Markets Cap Best January for Over a Decade Stock Market Analysis Traders Take Profits Stock Market Analysis Markets Reach Bull Market Territory Stock Market Analysis US Markets Ease Near All Time Highs Markets Higher As Investors Play Catch Up Weekly Market Wrap Investing in 2013 continued Part 9 Stock Trading Tips for All Types of Market Environments Stock Market Analysis Markets Higher As Investors Play Catchup Stock Market Analysis Markets Cautious Ahead Of Chinese Data Archives

    Original URL path: http://blog.traderdealer.com.au/2012/04/27/asx-company-news-novogen-subsidiary-granted-us-patent/ (2013-02-03)
    Open archived version from archive

  • Cancer Treatment | Online Stockmarket Trading Update
    Inc an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism announced that the US Patent and Trademark Office has issued Patent No 8 163 795 covering the company s lead drug candidate ME 143 for use in treating cancer The patent is expected to provide protection until September 2025 The company also announced that it has received notices of allowance from the Japanese Patent Office for two patents that cover the ME 143 and ME 344 compositions of matter respectively and their use in treating cancer This key US patent for ME 143 follows on the heels of a related patent for ME 344 as well as a composition patent for both compounds solidifying the intellectual property position surrounding our two lead oncology drug candidates said Daniel P Gold PhD President and Chief Executive Officer of Marshall Edwards As we prepare for our upcoming Phase II clinical trials we believe our strong patent estate will help to facilitate our partnering efforts both in the US and in high growth markets abroad Marshall Edwards owns exclusive worldwide rights to all of its drug candidates including ME 143 and ME 344 The company s intellectual property portfolio now includes 15 issued US patents at least 12 additional US patent applications and more than 70 issued foreign patents and 50 foreign patent applications Marshall Edwards Inc is a San Diego based oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism Novogen Limited NRT is an Australian biotechnology company based in Sydney Australia Novogen conducts research and development on oncology therapeutics through its subsidiary Marshall Edwards Inc and is developing glucan technology through its subsidiary Glycotex Inc www novogen com Tags Cancer treatment Marshall Edwards Novogen NRT Patent Granted Posted in ASX Company News No Comments ASX Company News Prima BioMed Granted Ovarian Cancer Patent Thursday April 12th 2012 Australian cancer treatment development company Prima BioMed Ltd PRR is pleased to announce that it has received Notification of Grant by the Canadian Patent Office for its ovarian cancer vaccine CvacTM Patent number 2304952 is titled Mannose receptor bearing cell line and antigen composition and expires on 29 September 2018 The patent has also been granted in Australia Europe and Japan The granted patent claims are method of composition and protect the formulation of Prima s autologous dendritic cell vaccine CVacTM CVacTM is composed of a patients own dendritic cells pulsed with the cancer antigen Mucin 1 conjugated to oxidised mannan fusion protein The pulsed dendritic cells are then reinjected into the patient to stimulate an immune response to the Mucin 1 cancer antigen CVacTM is Prima BioMed s lead development product It is a vaccine therapy treatment for ovarian cancer sufferers that is administered post surgery and post chemotherapy to attempt to delay the relapse and control metastases There is a large un met medical need for new treatments for ovarian cancer which has a very high morbidity rate There are currently no maintenance based therapy products commercially available for this disease Prima BioMed is an ASX listed Australian health care company The Company is focused on technologies in the fields of cancer immunotherapy and immunology Prima s lead product is CVacTM ovarian cancer therapy treatment www primabiomed com au Tags Biotechnology Cancer treatment Patent Granted Prima Biomed PRR Posted in ASX Company News No Comments ASX Company News Viralytics Granted Chinese Blood Cancer Patent Friday March 30th 2012 Viralytics Limited VLA is pleased to announce the receipt of a notice to grant a patent in China involving the use of a panel of Coxsackie A viruses including CAVATAKTM in the treatment of the blood cancer multiple myeloma The scope of this application covers the use of Coxsackieviruses A13 A15 A18 and A21 CAVATAKTM in the manufacture of a medication for treating multiple myeloma Furthermore the application covers the use of the above listed Coxsackie A viruses in the laboratory removal of malignant multiple myeloma cells within auto grafts prior to autologous stem cell transplantation Multiple myeloma is a type of cancer that begins in white blood cells that produce antibodies Approximately 22 000 new cases and 11 000 deaths are expected from multiple myeloma within the US in 2012 CAVATAKTM is currently being evaluated in a US Phase II clinical trial in late stage melanoma patients under an Investigational New Drug application allowed by the US Food and Drug Administration Viralytics VLA principal asset is the intellectual property relating to CAVATAKTM an Oncolytic Virus technology CAVATAKTM is the trade name for Viralytics proprietary formulation of the Coxsackievirus Type A21 CVA21 EVATAKTM is the trade name for Viralytics proprietary formulation of the Echovirus Type 1 EV1 CVA21 and EV1 are viruses that occur naturally in the community CVA21 and EV1 attach to the outside of cells using a specific receptor on the cell s surface like a key fitting a lock CVA21 uses the receptors intercellular adhesion molecule 1 ICAM 1 and or decay accelerating factor DAF to bind and infect target cells Both of these receptor proteins have been demonstrated to be highly expressed on multiple cancer types including melanoma prostate cancer breast cancer multiple myeloma and others EV1 uses the receptor integrin α2β1 alpha 2 beta 1 receptorto bind and infect target cells www viralytics com Tags Biotechnology Cancer treatment Patent Granted Viralytics VLA Posted in ASX Company News No Comments ASX Company News Viralytics Granted Cancer Virus Patent Thursday February 16th 2012 Viralytics Limited VLA is pleased to announce the granting of a patent by the United States Patent and Trademark Office covering a Coxsackie A virus capable of infecting cancer cells substantially in the absence of intercellular adhesion molecule 1 ICAM 1 Dr Darren Shafren Viralytics Chief Scientific Officer said CAVATAKTM targets and destroys cancerous cells following binding to surface expressed ICAM 1 The generation of this novel Coxsackie A virus that can infect cancer cells in the absence of ICAM 1 expands the range of cancers that Viralytics panel of

    Original URL path: http://blog.traderdealer.com.au/tag/cancer-treatment/ (2013-02-03)
    Open archived version from archive

  • Marshall Edwards | Online Stockmarket Trading Update
    Edwards Furthermore this demonstrates our commitment to further strengthening the intellectual property portfolio we acquired earlier this year which will be essential for partnering any of our drug candidates and enhancing shareholder value Marshall Edwards completed the acquisition of its isoflavone based intellectual property portfolio including worldwide rights to lead oncology drug candidates ME 143 and ME 344 from Novogen Limited in May 2011 The portfolio now includes 11 issued US patents at least 14 US patent applications at least 40 issued foreign patents and at least 80 foreign patent applications Marshall Edwards Inc is a San Diego based oncology company focused on the clinical development of novel anti cancer therapeutics The company s lead programs focus on two families of small molecules that result in the inhibition of tumour cell metabolism Novogen Limited NRT is an Australian biotechnology company based in Sydney Australia Novogen conducts research and development on oncology therapeutics through its subsidiary Marshall Edwards Inc and is developing glucan technology through its subsidiary Glycotex Inc www novogen com http www traderdealer com au Fundamentals nrt Tags Cancer Cures Cancer treatment Marshall Edwards Novogen NRT Patent Granted Posted in ASX Company News No Comments ASX Company News Novogen Enters Cancer Research Joint Venture With Ausio Pharmaceuticals Monday October 31st 2011 Marshall Edwards Inc an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism a subsidiary of Novogen NRT and Ausio Pharmaceuticals LLC a biopharmaceutical company focused on the development of safe and effective medicines for the aging population announced the signing of an exclusive royalty bearing licence agreement The agreement gives Ausio exclusive worldwide rights under certain Marshall Edwards patents to develop manufacture and sell products utilising the isoflavone metabolite known as equol for non oncology applications In exchange Marshall Edwards is entitled to receive royalty payments on sales of any potential Ausio products that contain equol In addition the agreement gives Marshall Edwards a royalty free licence to certain issued manufacturing related intellectual property owned by Ausio We are very pleased to enter into this licencing agreement with Ausio our first since completing the acquisition of our isoflavone based intellectual property portfolio earlier this year said Daniel P Gold PhD President and Chief Executive Officer of Marshall Edwards This agreement demonstrates our commitment to maximising the value of these assets while maintaining our focus on the clinical development of our two current lead oncology drug candidates ME 143 and ME 344 Ausio Pharmaceuticals LLC is a private biotechnology development company focused on the advancement of safe and effective medicines for the aging population Ausio was founded in 2006 by Richard Jackson PhD based on technologies licensed from the Australian Health and Nutrition Association and Cincinnati Children s Hospital Medical Center The Company has garnered a strong patent position for its lead compound AUS 131 also referred to as S equol It has rapidly developed AUS 131 by working with excellent service providers Ausio s strategic goal is to collaborate with international pharmaceutical partners

    Original URL path: http://blog.traderdealer.com.au/tag/marshall-edwards/ (2013-02-03)
    Open archived version from archive

  • ASX Company News: Phylogica Granted Australian Patent | Online Stockmarket Trading Update
    a biotechnology company based in Perth Australia and the UK with a world class drug discovery platform harnessing the rich biodiversity of nature to discover novel peptide therapeutics www phylogica com Tags Biotechnology Patent Granted Peptides Phylogica PYC ASX Company News G8 Education Acquires Six New Childcare Centres ASX Company News Novogen Subsidiary Granted US Patent This entry was posted on Friday April 27th 2012 at 6 03 am and is filed under ASX Company News You can follow any responses to this entry through the RSS 2 0 feed You can leave a response or trackback from your own site Leave a Reply Click here to cancel reply Name required Mail will not be published required Website RSS Feed Twitter Follow Us Sign up to our free weekly e newsletter Feel inspired Start trading Recent Post Markets Cap Best January Performance for Over a Decade Weekly Market Wrap The Covered Call Collar Part 3 1 of Options Trading for All Types of Market Environments Stock Market Analysis Markets Cap Best January for Over a Decade Stock Market Analysis Traders Take Profits Stock Market Analysis Markets Reach Bull Market Territory Stock Market Analysis US Markets Ease Near All Time Highs Markets Higher As Investors Play Catch Up Weekly Market Wrap Investing in 2013 continued Part 9 Stock Trading Tips for All Types of Market Environments Stock Market Analysis Markets Higher As Investors Play Catchup Stock Market Analysis Markets Cautious Ahead Of Chinese Data Archives February 2013 January 2013 December 2012 November 2012 October 2012 September 2012 August 2012 July 2012 June 2012 May 2012 April 2012 March 2012 February 2012 January 2012 December 2011 November 2011 October 2011 September 2011 August 2011 July 2011 June 2011 May 2011 April 2011 March 2011 February 2011 January 2011 December 2010 November 2010

    Original URL path: http://blog.traderdealer.com.au/2012/04/27/asx-company-news-phylogica-granted-australian-patent/ (2013-02-03)
    Open archived version from archive

  • Peptides | Online Stockmarket Trading Update
    strengthens our core IP portfolio which already includes multiple granted worldwide patents It maintains Phylogica s dominant intellectual property position over the construction and screening of the world s most structurally diverse source of peptides Phylogica Limited PYC is a biotechnology company based in Perth Australia and the UK with a world class drug discovery platform harnessing the rich biodiversity of nature to discover novel peptide therapeutics www phylogica com Tags Biotechnology Patent Granted Peptides Phylogica PYC Posted in ASX Company News No Comments RSS Feed Twitter Follow Us Sign up to our free weekly e newsletter Feel inspired Start trading Recent Post Markets Cap Best January Performance for Over a Decade Weekly Market Wrap The Covered Call Collar Part 3 1 of Options Trading for All Types of Market Environments Stock Market Analysis Markets Cap Best January for Over a Decade Stock Market Analysis Traders Take Profits Stock Market Analysis Markets Reach Bull Market Territory Stock Market Analysis US Markets Ease Near All Time Highs Markets Higher As Investors Play Catch Up Weekly Market Wrap Investing in 2013 continued Part 9 Stock Trading Tips for All Types of Market Environments Stock Market Analysis Markets Higher As Investors Play Catchup Stock Market Analysis Markets Cautious Ahead Of Chinese Data Archives February 2013 January 2013 December 2012 November 2012 October 2012 September 2012 August 2012 July 2012 June 2012 May 2012 April 2012 March 2012 February 2012 January 2012 December 2011 November 2011 October 2011 September 2011 August 2011 July 2011 June 2011 May 2011 April 2011 March 2011 February 2011 January 2011 December 2010 November 2010 October 2010 September 2010 August 2010 July 2010 June 2010 May 2010 April 2010 March 2010 February 2010 January 2010 December 2009 November 2009 October 2009 September 2009 August 2009 July 2009 June 2009

    Original URL path: http://blog.traderdealer.com.au/tag/peptides/ (2013-02-03)
    Open archived version from archive

  • Phylogica | Online Stockmarket Trading Update
    new frontier of identifying peptides which not only get into cells but also exert therapeutically relevant effects against targets within cells About half of the discovery alliances that we are currently negotiating with the pharmaceutical and biotechnology industry are around the intracellular space Dr Watt continued The vast majority of therapeutic targets are found within cells yet most of these targets are not tractable with conventional drugs such as small molecules Phylogica Limited PYC is a biotechnology company based in Perth Australia and Oxford UK with a world class drug discovery platform harnessing the rich biodiversity of nature to discover novel peptide therapeutics The Company was incorporated in 2001 as a spin out from the Telethon Institute for Child Health Research Perth Australia and the Fox Chase Cancer Centre Philadelphia USA The Company s drug discovery platform is based on its proprietary Phylomer libraries of natural peptides which have been optimised by evolutionary selection to have stable drug like structures Phylogica offers fully integrated drug discovery services to the pharmaceutical industry utilising its Phylomer libraries and proprietary screening technologies Its current partners include Roche MedImmune AstraZeneca Pfizer and Janssen Biotech Johnson Johnson www phylogica com http www traderdealer com au fundamentals pyc Tags Biotechnology Peptide Drugs Phylogica PYC Stroke Treatment Posted in ASX Company News No Comments ASX Company News Phylogica Enters JV Agreement With Pfizer Tuesday December 21st 2010 Phylogica Ltd PYC a public Australian drug discovery company announced today that it has entered into a collaboration and licensing agreement with Pfizer to discover novel peptide based vaccines Phylogica will employ its proprietary Phylomer drug discovery platform to identify Phylomer peptides suitable for further evaluation Under the agreement Phylogica grants Pfizer certain rights including an option to license any resulting Phylomers for further research development and commercialisation of novel peptide based vaccines derived from such Phylomers Under the terms of the agreement Phylogica will receive an upfront payment of US 500 000 In addition Phylogica is eligible to receive a commercial license payment and is also eligible to receive preclinical clinical and other milestone payments of up to US 134 million as well as royalties on worldwide sales Dr Paul Watt the founder and CEO of Phylogica said We are delighted to be working with Pfizer This alliance supports the potential utility of Phylogica s Phylomer drug discovery platform for peptide based drug discovery With the present announcement Phylogica has now entered into three alliances with global pharmaceutical companies within the last 12 months Phylogica Limited PYC is biotechnology company based in Perth Australia and Oxford UK with a world class drug discovery platform harnessing the rich biodiversity of nature to discover novel peptide therapeutics Phylogica s strategy is to accelerate cash sustainability by focusing on collaborative drug discovery partnerships The Company s Phylomer libraries have been optimised by natural evolutionary selection for peptides with stable drug like structures www phylogica com http www traderdealer com au Fundamentals pyc Tags Biotechnology JV Agreement Pfizer Phylogica PYC Posted in ASX

    Original URL path: http://blog.traderdealer.com.au/tag/phylogica/ (2013-02-03)
    Open archived version from archive

  • Webinar Playback: Market Analyser 7 Watchlists | Online Stockmarket Trading Update
    This entry was posted on Friday March 30th 2012 at 3 34 pm and is filed under Market Analyser 7 You can follow any responses to this entry through the RSS 2 0 feed You can leave a response or trackback from your own site Leave a Reply Click here to cancel reply Name required Mail will not be published required Website RSS Feed Twitter Follow Us Sign up to our free weekly e newsletter Feel inspired Start trading Recent Post Markets Cap Best January Performance for Over a Decade Weekly Market Wrap The Covered Call Collar Part 3 1 of Options Trading for All Types of Market Environments Stock Market Analysis Markets Cap Best January for Over a Decade Stock Market Analysis Traders Take Profits Stock Market Analysis Markets Reach Bull Market Territory Stock Market Analysis US Markets Ease Near All Time Highs Markets Higher As Investors Play Catch Up Weekly Market Wrap Investing in 2013 continued Part 9 Stock Trading Tips for All Types of Market Environments Stock Market Analysis Markets Higher As Investors Play Catchup Stock Market Analysis Markets Cautious Ahead Of Chinese Data Archives February 2013 January 2013 December 2012 November 2012 October 2012 September 2012 August 2012 July 2012 June 2012 May 2012 April 2012 March 2012 February 2012 January 2012 December 2011 November 2011 October 2011 September 2011 August 2011 July 2011 June 2011 May 2011 April 2011 March 2011 February 2011 January 2011 December 2010 November 2010 October 2010 September 2010 August 2010 July 2010 June 2010 May 2010 April 2010 March 2010 February 2010 January 2010 December 2009 November 2009 October 2009 September 2009 August 2009 July 2009 June 2009 May 2009 April 2009 March 2009 February 2009 January 2009 December 2008 November 2008 October 2008 September 2008 August 2008 July 2008

    Original URL path: http://blog.traderdealer.com.au/2012/03/30/webinar-playback-market-analyser-7-watchlists/ (2013-02-03)
    Open archived version from archive



  •